2RH Stock Overview A specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
RedHill Biopharma Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for RedHill Biopharma Historical stock prices Current Share Price US$8.00 52 Week High US$89.50 52 Week Low US$5.65 Beta 3.67 1 Month Change 0% 3 Month Change 12.28% 1 Year Change 18.52% 3 Year Change -99.69% 5 Year Change -99.85% Change since IPO -99.93%
Recent News & Updates
Redhill Biopharma Ltd. Announces Positive Results from New in Vivo Studies of Opaganib as A Treatment for GI-ARS Dec 10
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement Sep 06
Redhill Biopharma Ltd. Announces Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in Covid-19 Mortality Sep 04
New major risk - Financial position Aug 30
RedHill Biopharma Ltd. Announces the Launch of Talicia (Omeprazole Magnesium, Amoxicillin and Rifabutin) in the United Arab Emirates Aug 21
Redhill Biopharma Ltd. Announces Positive Obesity and Diabetes Results with Opaganib Aug 19 See more updates
Redhill Biopharma Ltd. Announces Positive Results from New in Vivo Studies of Opaganib as A Treatment for GI-ARS Dec 10
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement Sep 06
Redhill Biopharma Ltd. Announces Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in Covid-19 Mortality Sep 04
New major risk - Financial position Aug 30
RedHill Biopharma Ltd. Announces the Launch of Talicia (Omeprazole Magnesium, Amoxicillin and Rifabutin) in the United Arab Emirates Aug 21
Redhill Biopharma Ltd. Announces Positive Obesity and Diabetes Results with Opaganib Aug 19
New major risk - Market cap size Aug 18
RedHill Biopharma Ltd., Annual General Meeting, Sep 17, 2024 Aug 07
RedHill Biopharma Ltd. Announces Publication of Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RHB-104 in Crohn's Disease Aug 01
RedHill Biopharma Ltd. Announces Resignation of Alla Felders as Member of the Board Jun 08
RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035 May 08
RedHill Biopharma Ltd Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study Apr 24
Full year 2023 earnings released: EPS: US$4.00 (vs US$46.29 loss in FY 2022) Apr 09 RedHill Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of $1.25 million. Apr 02
New minor risk - Financial data availability Mar 05
Redhill Biopharma Ltd. Announces New Publication of Data from Multiple Experiments in the International Journal of Molecular Sciences Feb 21 RedHill Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of $8 million. Jan 26
RedHill Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of $8 million. Jan 25
Investor sentiment deteriorates as stock falls 15% Jan 11
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola Dec 21
Investor sentiment deteriorates as stock falls 17% Dec 19
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement Dec 12
Investor sentiment improves as stock rises 612% Nov 29
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia with IP Protection Running to 2034 Nov 29
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia with IP Protection Running to 2034 Nov 28 RedHill Biopharma Ltd. announced that it has received $4.043808 million in funding Oct 13
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency Sep 23
Redhill Biopharma Ltd. Announces Fda Snda Approval for Talicia®? Sep 19
RedHill Biopharma Ltd. Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA) Sep 06
Second quarter 2023 earnings released Aug 18
RedHill Biopharma Ltd. Announces its Partner, Gaelan Medical LLC Receives Marketing Approval from United Arab Emirates Ministry of Health for Talicia Aug 03
RedHill Biopharma Ltd., Annual General Meeting, Aug 08, 2023 Jun 30
First quarter 2023 earnings released: EPS: US$20.00 (vs US$15.64 loss in 1Q 2022) Jun 12
RedHill Biopharma Ltd. Provides R&D Update May 23
RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency May 16
Redhill Biopharma Ltd. Announces Board Changes May 06
Full year 2022 earnings released: US$48.00 loss per share (vs US$84.03 loss in FY 2021) Apr 30
Redhill Biopharma Ltd. Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 for Oncology Support Feb 17
RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome Feb 16
RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease Jan 27
Redhill Biopharma Ltd. Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB 107 in Non-Hospitalized COVID-19 Jan 04 RedHill Biopharma Ltd. has completed a Composite Units Offering in the amount of $7.989775 million. Dec 07
RedHill Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of $8 million.
Third quarter 2022 earnings released: US$0.56 loss per share (vs US$0.46 loss in 3Q 2021) Nov 30
Redhill Biopharma Ltd. Announces Positive New Data with Opaganib for Nuclear Radiation Injury Nov 18
Forecast breakeven date pushed back to 2024 Nov 16
Insufficient new directors Nov 16
Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.53 loss in 2Q 2021) Nov 08
RedHill Biopharma Ltd. Provides Earnings Guidance for the Third Quarter Ended September 30, 2022 Nov 08
RedHill Biopharma Ltd. Presents New Talicia® Data Analyses At Obesity Week 2022 Nov 05
Insufficient new directors Nov 01
Redhill Biopharma Ltd. Announces Presentation of New Data Analyses for Talicia Oct 27
RedHill Biopharma Ltd. Announces Grant of New COVID-19 Treatment Patent for its Oral Broad-Acting Antiviral, Opaganib Oct 20
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency Oct 19
Redhill Biopharma Ltd. Announces Study Results Showing in Vitro Efficacy Against the Currently Dominant Omicron Covid-19 Sub-Variant BA.5 Oct 04
Insufficient new directors Oct 02
First quarter 2022 earnings released: US$0.33 loss per share (vs US$0.53 loss in 1Q 2021) Jun 24
RedHill Biopharma Ltd. to Report Q1, 2022 Results on Jun 23, 2022 Jun 18
RedHill Presents New Talicia Data Analyses at DDW 2022 May 26
Forecast breakeven date moved forward to 2023 Apr 28
RedHill Biopharma Ltd. Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro Apr 12
RedHill Biopharma Ltd., Annual General Meeting, May 12, 2022 Mar 31
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 18
RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19 Mar 03
Redhill Biopharma Ltd. Provides Earnings Guidance for Fourth Quarter of 2021 Feb 18
RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19 Feb 08
RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients Jan 14
RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI Dec 05
No longer forecast to breakeven Dec 03 RedHill Biopharma Ordinary Shares Deleted from Other OTC
Third quarter 2021 earnings: EPS in line with expectations, revenues disappoint Dec 01
Independent Director Alessandro Della Cha has left the company Nov 29
Independent Director Alessandro Della Cha has left the company Nov 29
Independent Director Alessandro Della Cha has left the company Nov 29
Independent Director Alessandro Della Cha has left the company Nov 29
Independent Director Alessandro Della Cha has left the company Nov 29
Independent Director Alessandro Della Cha has left the company Nov 28
Independent Director Alessandro Della Cha has left the company Nov 28
Independent Director Alessandro Della Cha has left the company Nov 28
Independent Director Alessandro Della Cha has left the company Nov 28
Independent Director Alessandro Della Cha has left the company Nov 28
Independent Director Alessandro Della Cha has left the company Nov 28
Independent Director Alessandro Della Cha has left the company Nov 28
Independent Director Alessandro Della Cha has left the company Nov 28
Independent Director Alessandro Della Cha has left the company Nov 28
Independent Director Alessandro Della Cha has left the company Nov 28
Independent Director Alessandro Della Cha has left the company Nov 27
Independent Director Alessandro Della Cha has left the company Nov 27 Shareholder Returns 2RH DE Pharmaceuticals DE Market 7D 0% -2.2% -2.0% 1Y 18.5% -15.6% 6.9%
See full shareholder returns
Return vs Market: 2RH exceeded the German Market which returned 8.3% over the past year.
Price Volatility Is 2RH's price volatile compared to industry and market? 2RH volatility 2RH Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2RH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 2RH's volatility change over the past year.
About the Company RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
Show more RedHill Biopharma Ltd. Fundamentals Summary How do RedHill Biopharma's earnings and revenue compare to its market cap? 2RH fundamental statistics Market cap €8.87m Earnings (TTM ) -€28.66m Revenue (TTM ) €3.52m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2RH income statement (TTM ) Revenue US$3.71m Cost of Revenue US$2.45m Gross Profit US$1.26m Other Expenses US$31.44m Earnings -US$30.17m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -23.56 Gross Margin 34.04% Net Profit Margin -813.97% Debt/Equity Ratio 0%
How did 2RH perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/11/16 04:28 End of Day Share Price 2024/08/19 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources RedHill Biopharma Ltd. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Edward Woo Ascendiant Capital Markets LLC null null BTIG Brandon Folkes Cantor Fitzgerald & Co.
Show 8 more analysts 
